65.

o.

A

es.

es,

70.

n

72

73.

7a

75.

Raoult D. Full-length tile: Eariy treatment of COVID-19 patients with hydroxychloroquine and azithromyein: À
reirospective analysis of 1061 cases in Marseille, France, Travel Mod Infect Dis. May 2020:101738.
doi:10.1016/) Imaid.2020.101738.

Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G. Continuous hydroxychloroquine or colohicine
therapy does not prevent infection wilh SARS-CoV-Z: Insights from a large heallheare database analysis.
Autoimmum Rev. May 2020:102586. d0i:10.1016j autrev.2020.102586,

 

Mathian A, Mahevas M, Rohmer d, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C,
Chazal T, Delahousse M, Devaux M, Euvrard R, Fadlallah J, Florens N, Haroche d, Hié M, Juara L, Lhote R,
Maillet T, Richard-Colmant G, Palluy JB, Pha M, Perard L, Remy P, Riviêre E, Sêne D, Sêve P, Morélot-
Panzini €, Viallard J-F, Virot J-S, Benameur N, Zahr N, Yssel H, Godeau B, Amoura Z. Clinical course of
coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erylhematosus under
Jong-term treatment with hydroxychloroquine, Ann Reu Dis. April 2020. doi:10.1138/annrheumdis-2020-
217566,

Vastarella M, Patri A, Annunziata MC, Cantelli M, Nappa P, Tasso M, Costa L, Caso F, Fabbrocini G. Joumal
Pre-proof Can hydroxyohioroquine be useful in the prevention of COVID-19? An Italian survoy in
dermatological and rheumatological patients already under treatment, 4 Am Acad Dermaio!. 2020.
doi;10.1016) jaad.2020.04.136.

Monti S, Batduzzi 8, Delvino P, Belis E, Quadreli VS, Montecucco C. Clinical course of COVID-1S in a series
of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rhheum Dis.
2020;79(5):667-868. doi:10.1136/annrheumáis-2020-217424.

 

 

Konig MF, Kim AH, Scheetz MH, Grasf ER, Licw JW, Simard J, Machado PM, Glanfrancesco M, Yazdany d,
Langguth D, Robinson PC. Baselino use of hydroxychloroquine in systemic lupus erythematosus does not
preclude SARS-CoV-2 infection and severe COVID-19, Ann Rheum Dis. May 2020.
doi-10.1136/ANNRHEUMDIS-2020-217690.

Chen Z, Hu J, Zhang Z, Jiang S, Han 5, Yan D, Zhuang R, HUB, Zhang Z. Efficacy of hydroxychloroquine in
patients wilh COVID-19: results of a randomized clinical trial. medRxiv. April 2020:2020.03.22.20040758.
d0i10.1101/2020.03.22.20040758.

Garlucei PM, Ahuja T, Petri C, Rajagopalan H, Jones S, Rahimian J, Org JR. Hydroxychloroquine and
azilhromyoin plus zinc vs hydraxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19
patients. doi:10.1101/2020.05,02.20080036.

 

Huang M, Li, Xiao F, Liang 4, Pang P, Tang T, Liu S, Chen B, Shu J, You Y, Li Y, Tang M, Zhou d, Jiang G,
Xiang J, Hong W, He S, Wang Z, Feng d, Lin G, Ye Y, Wu Z, LiY, Zhong B, Sun R, Hong Z, Liu d, Chen H,
Wang X, LIZ, Pei D, Tian L, Xia 4, Jiang S, Zhong N, Shan H. Preliminary evidence from a multicenter
prospectivo observational study of the safety and efficacy of chloroquine Tor the treatment of GOVID-19.
imedRxiv. May 2020:2020.04.26.20081059. doi:10.1101/2020.04.26.20081059.

Yu B, Wang DW, LiC. Hydroxychloroquine application is associated with a decreased mortality in critical il
patients with COVID-1S. medfxiv. May 2020:2020.04.27.20073379. doi:10.1101/2020.04.27 20073379.

Davido B, Lansaman T, Bessis S, Lawrence C, Alvarez J-C, MascittiH, Bouchand F, Moine P, Perronne V,
Gal A Le, Annane D, Perronne C, Truchis P De, Toam C-18 R. Hydroxychloroquine plus azithromyoin: a
potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)? medfxiv.
May 2020:2020.05.05.20088757. doi-10.1101/2020.05.05.20088757.

Barbosa Esper R, Souza da Silva R, Teiichi Costa Oikawa F, Machado Castro M, Razuk-Filho A, Benedito
Batista Junior P, Wilhelm Lotze S, Nunes da Rocha G, de Sá Cunha Filho R, Emanuel Barbosa de Oliveira S,
Leitão Ribeiro P, Cristina Vigar Martins V, Silva Braga Bueno F, Ligeiro Gonçalves Esper P, Fagundes
Parto E. Empiical Treatment with Hiyciroxychioroquine and Azilhromyein for Suspected Cases of COVID-19
Followed-up by Telemedicine.

Novales FJM de, Ramírez-Olivoncia G, Estébanez M, Dios B de, Herrero MD, Mata T, Borabia AM, Gutiérrez
G, Simón M, Ochoa A, Martinez Y, Aguirre A, Alcântara F de A, Fernández-González P, López E, Campos S,
Navarro M, Ballestor LE. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19
Patients: An Observational Study. May 2020. doi:10.20944/PREPRINTS202005.0057.V1.
